← IPO Calendar

Speciality Medicines IPO IPO

Mainline20 Mar 202624 Mar 2026
Open
20 Mar 2026
Close
24 Mar 2026
3
Allotment
Listing
Mon, Mar 30, 2026
Price Band
₹117 to ₹124
Issue Size
23,50,000 shares (agg. up to ₹29 Cr)
Lot Size
1,000 Shares
Listing Date
Mon, Mar 30, 2026
Latest GMP
₹0
Est. Gain
0%
✦ AI Insight

GMP Trend

30-03-20260Est. ₹124+0%
29-03-20260Est. ₹124+0%
28-03-20260Est. ₹124+0%

Live Subscription

CategorySubscription (times)
Total1.35x

Restated Financials (₹ Cr.)

Period Ended31 Oct 202531 Mar 202531 Mar 2024
Assets45.5739.9822.68
Total Income36.9358.5427.66
Profit After Tax6.068.612.93
EBITDA6.519.095.26
NET Worth36.4730.4215.06
Reserves and Surplus30.0423.989.95
Total Borrowing4.815.052.86
Amount in ₹ Crore

Peer Comparison

CompanyIssue TypeIssue SizeIssue PricePE RatioListing Day CloseListing Gain/Loss %LTP
Accretion Nutraveda Ltd.SME₹24.77 Cr₹12926.27₹191.20+48.22%₹262.00 (-0.70%)
KRM Ayurveda Ltd.SME₹77.49 Cr₹13517.32₹180.70+33.85%₹242.70 (-0.98%)
Curis Lifesciences Ltd.SME₹27.52 Cr₹12812.44₹141.00+10.16%₹105.05 (+2.79%)
Aptus Pharma Ltd.SME₹13.02 Cr₹7011.29₹84.84+21.20%₹249.35 (+2.66%)
Asston Pharmaceuticals Ltd.SME₹27.56 Cr₹12317.83₹124.95+1.59%₹73.50 (-2.00%)
Influx Healthtech Ltd.SME₹58.57 Cr₹9613.04₹126.20+31.46%₹290.00 (-0.60%)
Astonea Labs Ltd.SME₹37.67 Cr₹13527.36₹135.65+0.48%₹283.00 (-1.57%)
Accretion Pharmaceuticals Ltd.SME₹29.75 Cr₹10121.29₹82.95-17.87%₹166.00 (+3.33%)
Corona Remedies Ltd.Mainboard₹655.37 Cr₹106243.47₹1,438.40+35.44%₹2,064.90 (+0.13%)
Rubicon Research Ltd.Mainboard₹1,377.50 Cr₹48555.75₹628.20+29.53%₹1,419.00 (-3.11%)
Amanta Healthcare Ltd.Mainboard₹126.00 Cr₹12634.59₹141.75+12.50%₹165.27 (-1.98%)
Anlon Healthcare Ltd.Mainboard₹121.03 Cr₹9117.67₹91.73+0.80%₹15.18 (+0.53%)

Objects of the Issue

#Issue ObjectsEst Amt (₹ Cr.)
1Setting up of Research and Development (R&D) Centre at Revenue City Survey No. RV1/NA/61/1/50, Moje, Manda, Tal. Umargam, Dist. Valsad, Gujarat12.68
2Product Registration in International Markets and Product Development for sale in international markets2.99
3Funding for Marketing and Promotional Activities1.66
4To Meet Working Capital Requirements8.00
5General Corporate Purposes0.25
6Issue Expenses3.57
Total29.14

About Speciality Medicines IPO

Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals — including high-cost oral and injectable medications used to treat complex chronic conditions — across both domestic and international markets. The company’s portfolio includes a wide range of speciality pharmaceutical finished formulations products, which are available in various dosage forms such as tablets, capsules, creams, syrups, eye drops, gels, infusions, inhalers, injections, nasal sprays, ointments, ophthalmic solutions, oral solutions, sachets, and suspensions. The company operates via two models: (a) contract manufacturing of finished formulations for international distribution, and (b) marketing and distribution of sourced specialty pharmaceutical products. The company has expanded internationally with registered or pending products in countries like Jordan, Ethiopia, Uganda, Peru, and Namibia. Its distribution network builds strong relationships across over 20 states in India and more than 35 countries worldwide world. As of Feb 28, 2026, the company has 7 products registered overseas and 54 products are in the registr

Contact Details

Speciality Medicines Ltd. Address913, One World West, S.No.396, FP 119Village-Vejalpur, Ahmadabad CityAhmedabad, Gujarat, 380051+91 22 4604 5344investors.grievances@specialitymedicine.comVisit Website